ArticleCancer immunology, immunotherapy : CII2025
Discontinuation of immunotherapy and its effect on prognosis in recurrent or metastatic nasopharyngeal carcinoma patients: a retrospective analysis.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmunotherapy has become the standard first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). This study aims to explore the impact of discontinuation of immunotherapy within 1 year on survival prognosis in patients with R/M NPC. MATERIALS AND
methodsWe retrospectively collected the clinical characteristics, treatment regimens and hematological biomarkers of 114 patients with first-line R/M NPC in our unit. The patients were divided into two groups: discontinuation group with a duration of immunotherapy ≤ 12 months and continuation group with a duration of immunotherapy > 12 months. The Kaplan-Meier method was used to validate the effect of duration of immunotherapy on overall survival (OS) and progression-free survival (PFS). Univariate and multivariate Cox regression analyses were conducted on duration of immunotherapy for OS.
resultsThe median follow-up time was 25 months. The median PFS for the continuation group was 39 months, significantly better than the 24 months observed in the discontinuation group (p = 0.0042). The continued group also significantly extended patient OS (p = 0.00048), though the median OS for both groups had not yet reached the endpoint. The 2-year OS rate of the discontinued group was 33.3%, while that of the discontinued group was 59.4%. Duration of immunotherapy ≤ 12 months was an independent risk factor for OS in univariate Cox analysis (HR = 5.881 95%CI 1.931-17.917, p = 0.002) and multivariate Cox analysis (HR = 9.01 95%CI 1.924-42.192, p = 0.005).
conclusionsThe duration of immunotherapy > 12 months is associated with better OS in patients with first-line R/M NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.